Masaru Matsuda - 01 Dec 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Reporting Person's title: SVP General Counsel and Corporate Secretary
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Masaru Matsuda
Issuer symbol: ARQT
Transactions as of: 01 Dec 2025
Transactions value $: -$50,091
Form type: 4
Filing time: 03 Dec 2025, 17:24:39 UTC
Previous filing: 21 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Matsuda Masaru	Reporting Person's title: SVP General Counsel and Corporate Secretary	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE	/s/ Latha Vairavan, as Attorney-in-Fact for Masaru Matsuda	03 Dec 2025	0001798679

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Sale	-$50.1K	-1.66K	-1.09%	$30.23	151K	01 Dec 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026.
F2	Includes 822 shares acquired under Arcutis Biotherapeutics, Inc. Employee Stock Purchase Plan on November 30, 2025.

Remarks:

Reporting Person's title: SVP General Counsel and Corporate Secretary